TOOsonix Granted U.S. Patent for Non-Invasive Dermatological Treatment

The U.S. Patent and Trademark Office has awarded a patent to TOOsonix A/S  for its key dermatological treatment technologies. The U.S. patent and already granted patents in Europe and China complete the first phase of securing intellectual property rights for TOOsonix’s technology in the major markets.

“Having patents in our three main markets has always been an essential milestone for the company. With the grant of the first and very strong patents in all three jurisdictions we are well prepared for broad market release in the near future,” Co-Founders Torsten Bove and Tomasz Zawada stated.
 
The patented technology’s key aspects are the precise and non-invasive treatment of dermis and epidermis using therapeutic ultrasound guided in real-time by an optical system, which enhances both patient safety and efficacy. The technology is embedded in the company’s first product—TOOsonix System ONE-M, which is currently in the late phase of approvals for medical treatments. A series of recently published clinical case studies has shown the system provides superior results in various dermatological conditions such as actinic keratosis, basal cell carcinoma, condylomas, vascular malformations, seborrheic keratosis, Kaposi’s sarcoma and others originating in the skin’s epidermis. The company is currently conducting clinical studies on Basal Cell Carcinoma and Cutaneous Neurofibroma treatments.
 
“Our strategy on protecting intellectual property rights is key to the future success of this fascinating technology,” said Lone Schoett Kunoee, CEO of Consolidated Holdings A/S and TOOsonix board chairman. “We invested in TOOsonix from the very early phase as we saw a great potential in developing the technology into a broader range of applications as well as commercializing the product to a world market. Obtaining and developing patents and IPR are critical aspects of this journey, and we are convinced that this will secure strong commercial implementation”.
 
TOOsonix is a Danish company pioneering therapeutic ultrasound for dermatological indications with its patented high-frequency focused ultrasound device. The company was founded in 2017 on the foundations of more than 35 years’ experience in ultrasonic technology and devices. The company has financial backing from Consolidated Holdings A/S, one of Denmark’s most successful private investor companies.